Abstract
Abstract BACKGROUND AND AIMS Proteinuria is strongly associated with the risk of CKD progression in non-diabetic and diabetic patients. SGLT2 inhibitors, as a promising new class, may provide protective effects for the kidney. Even though various studies have been conducted in this area, especially in diabetic patients, little information is available about how SGLT2 inhibitors affect proteinuria, kidney function or blood pressure in non-diabetic patients. Due to the lack of adequate information in previous studies, in this study, we investigated the effect of SGLT2 inhibitors on protein excretion and glomerular filtration rate (GFR) in patients with proteinuria. METHOD The present study was conducted as a single-group clinical trial (before and after). Thirty patients with proteinuria were enrolled. In addition to conventional treatment, empagliflozin 10 mg daily was administered. Height, weight, body mass index (BMI), GFR content, systolic and diastolic blood pressure, proteinuria and side effects in patients at the study's beginning and end were evaluated and recorded. In the end, the data were collected and analysed statistically. RESULTS In the present study, 30 patients with proteinuria were followed for 13.26 ± 5.90 weeks. The mean proteinuria of patients decreased significantly during the follow-up period (from an average of 1007.9 mg at the beginning of the study to 672.33 mg at the end (P < .05)). There was no significant difference in serum creatinine levels and glomerular filtration levels (P > .05). However, there was a significant decrease in blood pressure (systolic and diastolic) (P < .05). BMI and patients' weight were decreased compared to the beginning of the study, but this difference was not statistically significant (P > .05). Hypoglycaemia or hypokalemia did not occur in any of the patients. In 10% of patients, temporary dysuria was seen. Also, urinary tract infection was recorded in one patient (3.3%). In 3.3% of patients, the drug was discontinued due to intolerance. CONCLUSION The results of this study demonstrated that administration of empagliflozin significantly decreases proteinuria in non-diabetic patients with chronic kidney disease. However, further studies are recommended in this area.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
